Vericel Corporation

Financials

Activos totales 205.61 M243.71 M273 M353.66 M432.72 M487.97 M Total de pasivos 71.35 M73.24 M80.73 M127.7 M140.75 M133.33 M Capital total 134.26 M170.46 M192.27 M225.95 M291.97 M354.64 M Total de pasivos y patrimonio neto 205.61 M243.71 M273 M353.66 M432.72 M487.97 M Deuda total —————— Deuda neta ——————

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan. In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before. In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.

VCEL

Financials

Vericel Corporation

Noticias

Las acciones de Vericel alcanzan mínimos de 52 semanas en 29,21 dólares

Leerink reitera calificación de Mejor Rendimiento para Vericel con objetivo de 46 dólares

Leerink reitera calificación Outperform en Vericel con objetivo de $46

Leerink reiterates Outperform on Vericel stock, $46 target

Vericel en la Conferencia TD Cowen: fuerte crecimiento y expansión estratégica

Vericel en Conferencia TD Cowen: Fuerte crecimiento y expansión estratégica

Vericel at TD Cowen Conference: Strong Growth and Strategic Expansion

Vericel obtiene aprobación de la FDA para producir MACI en nueva instalación

Vericel wins FDA approval for MACI production at new facility

H.C. Wainwright eleva el precio objetivo de Vericel por crecimiento de ingresos

H.C. Wainwright eleva precio objetivo de Vericel por crecimiento en ingresos

H.C. Wainwright raises Vericel stock price target on revenue growth